EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical and cost-effectiveness of the digital intervention, MyWay Diabetes, in people with type 2 diabetes living in Greater Manchester during the COVID-19 pandemic

Rathi Ravindrarajah iD, Matthew Gittins, Luke Paterson, Gabriel Rogers, George Tilson, Deborah J Wake, Doogie Brodie, Scott G Cunningham, Naresh Kanumilli, Ewan Jones, Peter Elton, Nicola Milne iD und 4 weitere

PLOS One · 25.06.2026 · 21 (6) · e0349232

DOI: 10.1371/journal.pone.0349232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 25.06.2026. Verfasst von Rathi Ravindrarajah und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nursing, Midwifery & Social Work, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovate UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

We aimed to assess a) whether using the digital intervention, MyWay Diabetes (MWD), during the COVID-19 pandemic in Greater Manchester was associated with improvements in glycaemia and cardiovascular risk factors; and b) the cost-effectiveness of MWD.

Methods

From 01 st July 2019–30 th April 2022, we assessed risk factor changes in MWD users (n = 507) with T2D, adjusting for changes in a matched control group of non-users (n = 10,135). Economic evaluation was conducted using United Kingdom Prospective Diabetes Study Outcomes Model version 2.1 simulating 1,000 patients over 40-years based on observed risk factor changes.

Results

Over 2-years follow-up, MWD use was associated with a clinically significant reductions in HbA1c of 3.1 (95%CI: 1.5 to 4.6) mmol/mol and decreases in systolic blood pressure (1.4 (0.2 to 2.6) mmHg) and cholesterol (0.1 (0.02 to 0.2) mmol/L) when compared to non-users. Including medication costs, MWD generated more health (0·015 QALYs) and lower costs (−£67 per person) compared to usual care. Excluding medication costs, MWD generated QALYs at a cost of £389 each, below the NICE threshold of £20,000–30,000/QALY.

Interpretation

At population level, the risk factor changes associated with MWD are likely to reduce long-term diabetes-related complications risks and the intervention appears cost-effective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2COVID-19HumansCost-Benefit AnalysisCost-Effectiveness AnalysisFemaleMaleMiddle AgedAgedUnited KingdomGlycated HemoglobinDigital HealthPandemicsSARS-CoV-2Blood GlucoseRisk Factors

Substanzen

Glycated HemoglobinBlood Glucose

Autor:innen und Institutionen

  • Division of Nursing, Midwifery & Social Work, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
  • Division of Informatics, Imaging and Data Science, School of Health Sciences, Faculty of Biology, Medicine, and Health, The University of Manchester, Manchester, United Kingdom.
  • Manchester Centre for Health Economics, Division of Population Health, Health Services Research & Primary Care, University of Manchester, Manchester, United Kingdom.
  • My Way Digital Health, Dundee, United Kingdom.
  • Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom.
  • Population Health & Genomics, School of Medicine, University of Dundee, Dundee, United Kingdom.

ORCID-Profile: Rathi Ravindrarajah, Nicola Milne, Michael Morgan-Curran, Evangelos Kontopantelis, Thomas Allen

Förderung

  • Innovate UK

Zitieren

APA

Ravindrarajah, R., Gittins, M., Paterson, L., Rogers, G., Tilson, G., Wake, D. J., Brodie, D., Cunningham, S. G., Kanumilli, N., Jones, E., Elton, P., Milne, N., Morgan-Curran, M., Kontopantelis, E., Allen, T., & Rutter, M. K. (2026). Clinical and cost-effectiveness of the digital intervention, MyWay Diabetes, in people with type 2 diabetes living in Greater Manchester during the COVID-19 pandemic. PLOS One, 21(6), e0349232. https://doi.org/10.1371/journal.pone.0349232

Vancouver

Ravindrarajah R, Gittins M, Paterson L, Rogers G, Tilson G, Wake DJ, et al. Clinical and cost-effectiveness of the digital intervention, MyWay Diabetes, in people with type 2 diabetes living in Greater Manchester during the COVID-19 pandemic. PLOS One. 2026;21(6):e0349232. doi:10.1371/journal.pone.0349232

BibTeX
@article{Ravindrarajah2026,
  author = {Ravindrarajah, Rathi and Gittins, Matthew and Paterson, Luke and Rogers, Gabriel and Tilson, George and Wake, Deborah J and Brodie, Doogie and Cunningham, Scott G and Kanumilli, Naresh and Jones, Ewan and Elton, Peter and Milne, Nicola and Morgan-Curran, Michael and Kontopantelis, Evangelos and Allen, Thomas and Rutter, Martin K},
  title = {Clinical and cost-effectiveness of the digital intervention, MyWay Diabetes, in people with type 2 diabetes living in Greater Manchester during the COVID-19 pandemic},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {6},
  pages = {e0349232},
  doi = {10.1371/journal.pone.0349232}
}
Kostenlos starten →